Vericel Corporation
General ticker "VCEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B (TTM average)
Vericel Corporation follows the US Stock Market performance with the rate: 45.2%.
Estimated limits based on current volatility of 1.8%: low 39.76$, high 41.25$
Factors to consider:
- Total employees count: 398 (+11.5%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Regulatory and compliance, Product development failure, Supply chain disruptions, Inability to raise capital, Geopolitical risks
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [31.80$, 52.81$]
- 2026-12-31 to 2027-12-31 estimated range: [33.69$, 55.59$]
Financial Metrics affecting the VCEL estimates:
- Positive: with PPE of 120.0 at the end of fiscal year the price was neutral
- Positive: -4.23 < Operating profit margin, % of 4.00
- Negative: Investing cash flow per share per price, % of -2.34 <= -0.64
- Negative: 0.01 < Interest expense per share per price, % of 0.03
- Positive: 0.28 < Operating cash flow per share per price, % of 2.76
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 3.27
- Negative: negative Industry operating cash flow (median)
Short-term VCEL quotes
Long-term VCEL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $197.52MM | $237.22MM | $276.26MM |
| Operating Expenses | $203.98MM | $232.71MM | $265.21MM |
| Operating Income | $-6.46MM | $4.52MM | $11.04MM |
| Non-Operating Income | $4.10MM | $5.99MM | $6.33MM |
| Interest Expense | $0.60MM | $0.61MM | $0.63MM |
| R&D Expense | $21.04MM | $24.80MM | $27.56MM |
| Income(Loss) | $-2.37MM | $10.51MM | $17.38MM |
| Taxes | $0.81MM | $0.15MM | $0.86MM |
| Net Income(Loss)* | $-3.18MM | $10.36MM | $16.52MM |
| Stockholders Equity | $225.95MM | $291.97MM | $354.64MM |
| Inventory | $13.09MM | $17.37MM | $17.56MM |
| Assets | $353.66MM | $432.72MM | $487.97MM |
| Operating Cash Flow | $35.31MM | $58.16MM | $51.91MM |
| Capital expenditure | $27.51MM | $63.97MM | $27.16MM |
| Investing Cash Flow | $-3.13MM | $-79.03MM | $-43.94MM |
| Financing Cash Flow | $3.62MM | $19.05MM | $7.07MM |
| Earnings Per Share** | $-0.07 | $0.21 | $0.33 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.